Enhanced radiosensitivity of EC109 cells by inhibition of HDAC1 expression.
Histone deacetylase (HDAC) activity plays the role of deacetylation of histone and non-histone proteins, which can alter gene expression patterns and cell behavior potentially associated with malignant transformation. Aberrant expression of HDAC1 has been found in various types of cancers, which indicated that it might be a target for cancer therapy. In this study, overexpression of HDAC1 was found in esophageal cancer samples by real-time RT-PCR, compared with adjacent non-cancerous tissues. To further verify the possibility of anticancer treatment by silencing the increased HDAC1 in esophageal carcinoma cells, HDAC1 expression was knockdown using plasmid-based RNA interference (RNAi). Results showed the HDAC1 expression was efficiently inhibited and the acetylation of histone H3 was significantly increased by RNAi in EC109 cells. Increased apoptotic cell death was observed when HDAC1 expression was knockdown, which indicated that cells were more sensitive to radiation. Moreover, the results also showed DNA was more easily broken by radiation in EC109 cells when HDAC1 expression was knockdown, as measured by γH2AX foci and single-cell electrophoresis. Our data suggested that targeting the increased HDAC1 expression might be feasible for esophageal cancer therapy.
Zhang
Bo
B
Department of Medical Genetics, College of Basic Medicine, Third Military Medical University, 400038 Chongqing, China.
Wang
Yan
Y
Pang
Xueli
X
D017209:Apoptosis / Q000235:genetics / Q000528:radiation effects; D015153:Blotting, Western; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000528:radiation effects; D020552:Comet Assay; D004938:Esophageal Neoplasms / Q000235:genetics* / Q000378:metabolism; D005455:Fluorescent Antibody Technique; D055785:Gene Knockdown Techniques / Q000379:methods; D056284:Histone Deacetylase 1 / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D034622:RNA Interference; D011836:Radiation Tolerance / Q000235:genetics*; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014162:Transfection
C110550:HDAC1 protein, human; D056284:Histone Deacetylase 1
Oncogene. 2007 Jun 7;26(27):3963-71
17213813
Cell Cycle. 2004 May;3(5):534-5
15020838
Mutat Res. 1992 Jun;271(3):243-52
1378197
Nat Rev Drug Discov. 2006 Sep;5(9):769-84
16955068
Cancer Biol Ther. 2009 May;8(9):823-31
19270532
Int J Cancer. 2010 Mar 1;126(5):1246-55
19676051
Lancet Oncol. 2008 Feb;9(2):139-48
18207460
Biochem Biophys Res Commun. 2003 Oct 17;310(2):529-36
14521942
Biotechnol J. 2009 Mar;4(3):375-90
19296442
Histopathology. 2009 May;54(6):688-98
19438744
Cancer Res. 2006 Dec 1;66(23):11298-304
17145876
Breast Cancer Res Treat. 2005 Nov;94(1):11-6
16172792
BJU Int. 2010 Apr;105(8):1181-6
19681894
Oncogene. 2009 Apr 9;28(14):1714-24
19252524
J Biol Chem. 2005 Jul 22;280(29):26729-34
15937340
Mol Cell Biol. 2007 Jul;27(13):4784-95
17470557
Cancer Gene Ther. 2009 Aug;16(8):609-19
19444302
Cancer Gene Ther. 2010 Feb;17(2):120-30
19730451
Histopathology. 2008 Sep;53(3):267-77
18671804
Mol Cancer Ther. 2006 Aug;5(8):1967-74
16928817
Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):87-92
11134513
Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10014-9
10954755
Nat Biotechnol. 2002 May;20(5):505-8
11981566
Radiat Oncol. 2006 Aug 03;1:25
16887021
Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):534-42
19735878
Clin Cancer Res. 2009 Sep 1;15(17):5396-403
19706820
Oncol Rep. 2003 Mar-Apr;10(2):333-8
12579268
Lung Cancer. 2004 Nov;46(2):171-8
15474665
J Biol Chem. 1998 Mar 6;273(10):5858-68
9488723
Science. 1975 Nov 28;190(4217):893-4
1059262
Oncogene. 2007 Aug 13;26(37):5528-40
17694092
J Gynecol Oncol. 2008 Sep;19(3):185-90
19471575